Abstract
Bcl-2 (B-cell lymphoma 2) family proteins have been studied intensively due to their association with cancer and other human diseases. These proteins were originally associated with the regulation of outer mitochondrial membrane integrity and apoptosis. However, there is experimental evidence that suggests that several members of this family play instrumental roles in other cellular pathways including autophagy, endoplasmic reticulum signaling, mitochondrial morphology and synaptic activity among others. Bcl-2 family proteins have been explored using diverse experimental and theoretical methods to obtain structural information that can provide valuable insight for drug development. This review is focused on computational studies related to Bcl-2 family proteins. Different strategies are described and evaluated, such as Molecular Dynamics simulations, docking, and rational drug design with the aim of demonstrating the importance of structural details of either ligands or proteins. The relevance of the knowledge obtained using these tools to drug design is discussed.
Keywords: Apoptosis, Bcl-2, bioinformatics, cancer, molecular modeling, protein–protein interaction, structure-based drug design
Current Medicinal Chemistry
Title:Computational Modeling and Simulation of the Bcl-2 Family: Paving the Way for Rational Drug Design
Volume: 19 Issue: 36
Author(s): J. L. Rosas-Trigueros, I. Ilizaliturri-Flores, C. G. Benitez-Cardoza, J. Correa-Basurto and A. Zamorano-Carrillo
Affiliation:
Keywords: Apoptosis, Bcl-2, bioinformatics, cancer, molecular modeling, protein–protein interaction, structure-based drug design
Abstract: Bcl-2 (B-cell lymphoma 2) family proteins have been studied intensively due to their association with cancer and other human diseases. These proteins were originally associated with the regulation of outer mitochondrial membrane integrity and apoptosis. However, there is experimental evidence that suggests that several members of this family play instrumental roles in other cellular pathways including autophagy, endoplasmic reticulum signaling, mitochondrial morphology and synaptic activity among others. Bcl-2 family proteins have been explored using diverse experimental and theoretical methods to obtain structural information that can provide valuable insight for drug development. This review is focused on computational studies related to Bcl-2 family proteins. Different strategies are described and evaluated, such as Molecular Dynamics simulations, docking, and rational drug design with the aim of demonstrating the importance of structural details of either ligands or proteins. The relevance of the knowledge obtained using these tools to drug design is discussed.
Export Options
About this article
Cite this article as:
L. Rosas-Trigueros J., Ilizaliturri-Flores I., G. Benitez-Cardoza C., Correa-Basurto J. and Zamorano-Carrillo A., Computational Modeling and Simulation of the Bcl-2 Family: Paving the Way for Rational Drug Design, Current Medicinal Chemistry 2012; 19 (36) . https://dx.doi.org/10.2174/0929867311209066081
DOI https://dx.doi.org/10.2174/0929867311209066081 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibitors of the Immunoproteasome: Current Status and Future Directions
Current Pharmaceutical Design Oxidised Products of Cholesterol: Their Role in Apoptosis
Current Nutrition & Food Science ATP Site-Directed Inhibitors of Protein Kinase CK2: An Update
Current Topics in Medicinal Chemistry Adverse Effects and Drug Interactions of Biologic Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Biological Activity and Delivery of Peptide Nucleic Acids (PNA)-DNA Chimeras for Transcription Factor Decoy (TFD) Pharmacotherapy
Current Medicinal Chemistry CDC25A: A Rebel Within the CDC25 Phosphatases Family?
Anti-Cancer Agents in Medicinal Chemistry Inhibition of Intercellular Communication between Prostate Cancer Cells by A Specific Anti-STEAP-1 Single Chain Antibody
Anti-Cancer Agents in Medicinal Chemistry Structure of Multidrug-Resistance Proteins of the ATP-Binding Cassette (ABC) Superfamily
Current Medicinal Chemistry - Anti-Cancer Agents Atomic Force Microscopy: The Characterisation of Amyloid Protein Structure in Pathology
Current Topics in Medicinal Chemistry Protein-Protein Interaction Inhibitors: Small Molecules from Screening Techniques
Current Topics in Medicinal Chemistry Integrins in Drug Targeting-RGD Templates in Toxins
Current Pharmaceutical Design Quilizumab is an Afucosylated Humanized Anti-M1 Prime Therapeutic Antibody
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Relevance of Protein Isoforms in Proteomic Studies
Current Proteomics Bioinorganic Chemistry: The Study of the Fate of Platinum-Based Antitumour Drugs
Current Chemical Biology Toxin-Labeled Monoclonal Antibodies
Current Pharmaceutical Biotechnology Fluorescein-labeled Bacitracin and Daptomycin Conjugates: Synthesis, Fluorescence Imaging and Evaluation
Medicinal Chemistry Emerging Targets For Prostate Adenocarcinoma Therapy: How Molecular Biology May Drive Towards a More Tailored Approach
Current Drug Targets <sup>89</sup>Zr-PET Radiochemistry in the Development and Application of Therapeutic Monoclonal Antibodies and Other Biologicals
Current Topics in Medicinal Chemistry Multiple Protective Functions of Sigma1 Receptor
Current Protein & Peptide Science Drug Design Targeting the CXCR4/CXCR7/CXCL12 Pathway
Current Topics in Medicinal Chemistry